teal triangle graphic

Medical Education Grants

Medical Education Grants


Alkermes supports continuing medical education with grants for educational activities focused on pragmatic approaches to improving patient care and public health. We hope to contribute to an improved understanding of the underlying mechanisms of the diseases we research and their relevance to medications, as well as psychosocial interventions.

Grant funding may be available for activities, including live, print, enduring or web-based continuing medical education (CME) activities. Accredited CME activities are preferred.

Alkermes is currently accepting grant proposals related to:

  • Schizophrenia
  • Bipolar Disorder

Learners of interest:

  • Nurse Practitioners
  • Psychiatrists
  • Primary Care Providers
  • Physician Assistants
  • Social Workers
  • Pharmacists

For all questions, please contact: Med.Ed@alkermes.com

Apply now

Who May Apply

Only organizations based in the U.S. may apply. Medical education grants may be awarded to (i) nonprofit organizations with tax exempt status under the U.S. Internal Revenue Code or (ii) for-profit organizations that are accredited continuing medical education providers.


How to Apply

Requests must be submitted online by the educational provider. Submissions are due at least 90 days in advance of the activity date. 



Application portal


Areas of Interest

Alkermes is currently accepting proposals that address the topic areas listed below for Schizophrenia and Bipolar Disorder. Between June 21st and  July 19th, 2024, Alkermes will accept proposals for an RFP for continuing medical education programs specific to Bipolar Disorder.

Schizophrenia

  • Understanding patient-centered approaches to address one or more of the following challenges in the care of patients with schizophrenia:
    • Suboptimal therapeutic response
    • Gaps in medication adherence
    • Side effects associated with treatment
    • Management across stages of illness and transitions of care
    • Role of health inequities
    • Utilization of long-acting injectables (LAIs)
    • Co-occurring disorders

Bipolar Disorder

  • Understanding patient-centered approaches to address one or more of the following challenges in the care of patients with bipolar disorder:
    • Diagnostic accuracy
    • Assessment of mixed states
    • Role of health inequities
    • Suboptimal therapeutic response
    • Gaps in medication adherence
    • Side effects associated with treatment
    • Management across stages of illness and transitions of care
    • Co-occurring disorders

Request for Proposal Details - Bipolar Disorder (RFP#: 2024-RFP-BD-01) 

Statement of Need

On average, a diagnosis of bipolar disorder (BD) is delayed by 10 years from the first onset of symptoms.1,2 One study found that patients with BD face an average of 3.5 incorrect diagnoses and 4 different physicians before being accurately diagnosed.3 Differentiating BD from other psychiatric conditions is challenging due to comorbidity with other psychiatric diagnoses and difficulties differentiating symptoms that are due to intoxication or substance use disorder, anxiety disorder, attention deficit and hyperactivity disorder (ADHD), psychotic illness, borderline personality disorder or post-traumatic stress disorder.4 Management of bipolar disorder is also complex and requires a patient-centered approach that takes into account patients’ needs, goals and preferences.5 When implementing a treatment strategy into care, communication, open-mindedness, and flexibility is needed among both clinicians and patients.6 Establishing a positive therapeutic alliance through a shared decision-making approach engages patients in their treatment, while increasing adherence and improving outcomes.7,8 Thus, the need for clinician education on strategies to improve the diagnostic accuracy of BD and employ patient-centered approaches to effectively manage the disorder is critical. 


RFP details: 

  • RFP Areas of Interest for Bipolar Disorder (BD): Education around the importance to effectively: 
    1. Understand strategies to improve the screening, diagnosis, and assessment of patients with BD including mixed states
    2. Incorporate current evidence, patient-specific factors, and patients’ goals and preferences into treatment considerations for BD
    3. Employ patient-centered strategies and motivational techniques to engage patients in their treatment plans
  • The target audiences for learners are psychiatrists, psychiatric advanced practice nurse practitioners (APRNs), and primary care physicians focused on psychiatric care.
  • Proposals must be submitted to the Alkermes Grant Management System between June 21st and July 19th, 2024. Any proposal submitted outside of this period will not be eligible for RFP consideration.    
  • Proposals must reference RFP#: 2024-RFP-BD-01 in the program title.
  • Recipients will be selected by the Alkermes Grants Review Committee and notified in August 2024.
  • The maximum amount of funding available for this RFP is $300,000. Multiple individual grants of varying budget will be considered and evaluated and may be distributed among more than one provider.
  • Programs must be able to launch within 90 days of award date.

The following additional guidelines apply:

  • Innovative digital programs with patient-centric content, interactive elements, a focus on practical learning and clinical case-based studies will be prioritized. Ability to translate into Spanish a plus.
  • Programs that provide robust medical education outcomes plans will be prioritized. Ideal proposals will have specific plans for measuring program impact, including an assessment of the educational gains made and identification of any persistent educational gaps, with sub-analyses by learner type. Moore’s Level 5 outcomes measurement strongly preferred.
  • Priority will be given to programs that develop enduring materials and that identify best practices based on the consensus view of experts in the fields of bipolar disorder research and clinical practice.
  • Educational activities must be accredited (CME/CE), and collaborations between medical education companies, medical societies and academic institutions are strongly encouraged.

Who may apply:

  • Only organizations based in the U.S. may apply. Medical education grants may be awarded to (i) nonprofit organizations with tax exempt status under the U.S. Internal Revenue Code or (ii) for-profit organizations that are accredited continuing medical education providers.

How to apply:

  • Requests must be submitted online by the accredited provider. 

Click here to apply


References

1. Berk M, Dodd S, Callaly P, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord. 2007;103:181-186. 

2. Maier W, Zobel A, Wagner M. Schizophrenia and bipolar disorder: differences and overlaps. Curr Opin Psychiatry. 2006;19(2):165-170.

3. Hirschfeld R, Lewis L, Vornik L. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174. 

4. Huang H, Nissen N, Lim CT, Gören JL, Spottswood M, Huang H. Treating Bipolar Disorder in Primary Care: Diagnosis, Pharmacology, and Management. Int J Gen Med. 2022;15:8299-8314. doi:10.2147/IJGM.S386875

5. Carvalho AF, Firth J, Vieta E. Bipolar Disorder. New England Journal of Medicine. 2020;383(1):58-66. doi:10.1056/NEJMra1906193

6. Dixon LB, Holoshitz Y Nossel I. Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry. 2016;1591):13-20.

7. Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcomes Measures. 2014;5:43-62.

8. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71(suppl 2):20-26.

teal triangle graphic

Additional Information

Alkermes is committed to complying with all applicable regulations and codes pertaining to education grants. Alkermes follows the requirements of the General Compliance Program Guidance (GCPG) issued by the U.S. Department of Health and Human Services Office of the Inspector General (OIG), the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals ("PhRMA Code"), the FDA Guidance for Industry-Supported Scientific and Educational Activities and the Accreditation Council for Continuing Medical Education ("ACCME") Standards for Integrity and Independence in Accredited Continuing Education. Alkermes does not provide support for education programs that are intended to encourage, induce or influence any grant recipient to purchase, prescribe, refer, recommend, sell, administer or arrange for the purchase, sale or recommendation or formulary placement of any Alkermes product.


For questions, please contact: Med.Ed@alkermes.com.